Date: 2015-03-17
Type of information: Financing round
Company: Alize Pharma (France)
Investors: Octalfa (France) Sham Innovation Santé (France) Rhône-Alpes Création (France) Crédit Agricole Création (France) CEMA (France) TAB Consulting (France)
Amount: €1.8 million
Funding type: financing round
Planned used: Alizé Pharma will use the funds to conduct a pharmacology and lead optimization program on a family of peptides with anabolic effects on the bone. The I-HBD1 program will be performed in collaboration with Alizé Pharma III’s US partner New Paradigm Therapeutics, a spin-off from the University of North Carolina at Chapel Hill founded by Dr. David Clemmons. The aim of the program is to select a drug candidate that will enter development for the treatment of osteoporosis and other diseases with impaired bone metabolism in 2016. The I-HBD1 program aims to optimize and develop a new peptide derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro and in vivo studies have shown that this peptide can induce the formation of bone tissue by stimulating osteoblast differentiation and inhibiting osteoclast differentiation. This new mechanism of action is unique and may potentially lead to the development of a new therapeutic anabolic approach in treating osteoporosis and several other diseases associated with impaired bone metabolism.
Others: * On March 17, 2015, Alizé Pharma III SAS, an Alizé Pharma company specialized in the development of biopharmaceutical products to treat metabolic disorders and rare diseases, announced that it has raised €1.8 million (USD $1.94 million) in a first financing round. The funding round was supported by a syndicate of investors that included Sofimac Partners via their FCPI Emergence Innovation 1 seed capital fund, Octalfa, Sham Innovation Santé, Rhône-Alpes Création, Crédit Agricole Création, CEMA and TAB Consulting.
Therapeutic area: Bone diseases
